Filtered By:
Source: Cancers

This page shows you your search results in order of date. This is page number 15.

Order by Relevance | Date

Total 223 results found since Jan 2013.

Cancers, Vol. 11, Pages 202: SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro
In this study, we observed elevated SYK gene expression in neuroblastoma compared to neural crest and benign neurofibroma. While SYK protein was detected in the majority of examined neuroblastoma tissues it was less frequently observed in neuroblastoma cell lines. Depletion of SYK by siRNA and the use of small molecule SYK inhibitors significantly reduced the cell viability of neuroblastoma cell lines expressing SYK protein. Moreover, SYK inhibition decreased ERK1/2 and Akt phosphorylation. The SYK inhibitor BAY 613606 enhanced the effect of different chemotherapeutic drugs. Transient expression of a constitutive active SY...
Source: Cancers - February 10, 2019 Category: Cancer & Oncology Authors: Conny T ümmler Gianina Dumitriu Malin Wickstr öm Peter Coopman Andrey Valkov Per Kogner John Inge Johnsen Ugo Moens Baldur Sveinbj örnsson Tags: Article Source Type: research

Cancers, Vol. 11, Pages 189: Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells
a Gil Antiestrogenic adjuvant treatments are first-line therapies in patients with breast cancer positive for estrogen receptor (ER+). Improvement of their treatment strategies is needed because most patients eventually acquire endocrine resistance and many others are initially refractory to anti-estrogen treatments. The tumor microenvironment plays essential roles in cancer development and progress; however, the molecular mechanisms underlying such effects remain poorly understood. Breast cancer cell lines co-cultured with TNF-α-conditioned macrophages were used as pro-inflammatory tumor microenvironm...
Source: Cancers - February 6, 2019 Category: Cancer & Oncology Authors: Castellaro Rodriguez-Baili Di Tada Gil Tags: Article Source Type: research

Cancers, Vol. 11, Pages 176: Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy
d Therapeutic dendritic cell (DC) cancer vaccines rely on the immune system to eradicate tumour cells. Although tumour antigen-specific T cell responses have been observed in most studies, clinical responses are fairly low, arguing for the need to improve the design of DC-based vaccines. The incorporation of small interfering RNAs (siRNAs) against immunosuppressive factors in the manufacturing process of DCs can turn the vaccine into potent immune stimulators. Additionally, siRNA modification of ex vivo-expanded T cells for adoptive immunotherapy enhanced their killing potency. Most of the siRNA-targeted immune inhibit...
Source: Cancers - February 3, 2019 Category: Cancer & Oncology Authors: Mouldy Sioud Tags: Review Source Type: research

Cancers, Vol. 11, Pages 123: PKA at a Cross-Road of Signaling Pathways Involved in the Regulation of Glioblastoma Migration and Invasion by the Neuropeptides VIP and PACAP
-Marc Muller Glioblastoma (GBM) remains an incurable disease, mainly due to the high migration and invasion potency of GBM cells inside the brain. PI3K/Akt, Sonic Hedgehog (SHH), and PKA pathways play major regulatory roles in the progression of GBM. The vasoactive intestinal peptide (VIP) family of neuropeptides and their receptors, referred in this article as the “VIP-receptor system”, has been reported to regulate proliferation, differentiation, and migration in a number of tumor cell types and more particularly in GBM cells. These neuropeptides are potent activators of the cAMP/PKA pathw...
Source: Cancers - January 21, 2019 Category: Cancer & Oncology Authors: Souheyla Bensalma Soumaya Turpault Annie-Claire Balandre Madryssa De Boisvilliers Afsaneh Gaillard Corinne Chad éneau Jean-Marc Muller Tags: Article Source Type: research

Cancers, Vol. 11, Pages 108: Cancer Immunotherapy: Silencing Intracellular Negative Immune Regulators of Dendritic Cells
eng-Chi Yen Dendritic cells (DCs) are capable of activating adaptive immune responses, or inducing immune suppression or tolerance. In the tumor microenvironment, the function of DCs is polarized into immune suppression that attenuates the effect of T cells, promoting differentiation of regulatory T cells and supporting tumor progression. Therefore, blocking negative immune regulators in DCs is considered a strategy of cancer immunotherapy. Antibodies can target molecules on the cell surface, but not intracellular molecules of DCs. The delivery of short-hairpin RNAs (shRNA) and small-interfering RNAs (siRNA) should be ...
Source: Cancers - January 17, 2019 Category: Cancer & Oncology Authors: Yao-Hua Liu I-Jeng Yeh Ming-Derg Lai Kuan-Ting Liu Po-Lin Kuo Meng-Chi Yen Tags: Review Source Type: research

Cancers, Vol. 11, Pages 3: ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma
John Lunec MAPK and p14ARF–MDM2–p53 pathways are critical in cutaneous melanomas. Here, synergistic combination of the MEK inhibitor, trametinib, with MDM2 inhibitors, nutlin-3/RG7388/HDM201, and the mechanistic basis of responses, for BRAFV600E and p53WT melanoma cells, are reported. The combination treatments induced higher levels of p53 target gene transcripts and protein products, resulting in increased cell cycle arrest and apoptosis compared with MDM2 inhibitors alone, suggesting trametinib synergized with MDM2 inhibitors via upregulation of p53-dependent pathways. In addition, DUSP6 ...
Source: Cancers - December 20, 2018 Category: Cancer & Oncology Authors: Chiao-En Wu Tsin Shue Koay Arman Esfandiari Yi-Hsuan Ho Penny Lovat John Lunec Tags: Article Source Type: research

Cancers, Vol. 10, Pages 499: Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States
an-Barmatz Oncogenic properties, along with the metabolic reprogramming necessary for tumour growth and motility, are acquired by cancer cells. Thus, tumour metabolism is becoming a target for cancer therapy. Here, cancer cell metabolism was tackled by silencing the expression of voltage-dependent anion channel 1 (VDAC1), a mitochondrial protein that controls cell energy, as well as metabolic and survival pathways and that is often over-expressed in many cancers. We demonstrated that silencing VDAC1 expression using human-specific siRNA (si-hVDAC1) inhibited cancer cell growth, both in vitro and in mouse xenograft mode...
Source: Cancers - December 8, 2018 Category: Cancer & Oncology Authors: Arif Paul Krelin Shteinfer-Kuzmine Shoshan-Barmatz Tags: Article Source Type: research

Cancers, Vol. 10, Pages 347: NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells
Fujimoto Chiho Ohbayashi The nucleus accumbens-associated protein 1 (NACC1) is a transcription factor constitutively expressed in the urothelium, where it regulates cell growth, senescence, autophagy, and epithelial-mesenchymal transition. microRNA (miRNA) constitutes a class of small non-coding RNAs which are involved in cell proliferation, differentiation, and progression of tumors. miRNAs and their target molecules are utilized for molecular diagnosis of urothelial carcinoma. NACC1 is one of several putative target molecules of miR-331-3p, and is associated with cell proliferation in cancers such as prostate and ...
Source: Cancers - September 21, 2018 Category: Cancer & Oncology Authors: Kohei Morita Tomomi Fujii Hiroe Itami Tomoko Uchiyama Tokiko Nakai Kinta Hatakeyama Aya Sugimoto Makito Miyake Yasushi Nakai Nobumichi Tanaka Keiji Shimada Masaharu Yamazaki Kiyohide Fujimoto Chiho Ohbayashi Tags: Article Source Type: research

Cancers, Vol. 10, Pages 283: CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
utamaad Satayavivad Cholangiocarcinoma is a disease with a poor prognosis and increasing incidence and hence there is a pressing unmet clinical need for new adjuvant treatments. Protein kinase CK2 (previously casein kinase II) is a ubiquitously expressed protein kinase that is up-regulated in multiple cancer cell types. The inhibition of CK2 activity using CX-4945 (Silmitasertib) has been proposed as a novel treatment in multiple disease settings including cholangiocarcinoma. Here, we show that CX-4945 inhibited the proliferation of cholangiocarcinoma cell lines in vitro. Moreover, CX-4945 treatment induced the formati...
Source: Cancers - August 23, 2018 Category: Cancer & Oncology Authors: Jomnarong Lertsuwan Kornkamon Lertsuwan Anyaporn Sawasdichai Nathapol Tasnawijitwong Ka Ying Lee Philip Kitchen Simon Afford Kevin Gaston Padma-Sheela Jayaraman Jutamaad Satayavivad Tags: Article Source Type: research

Cancers, Vol. 10, Pages 180: KIAA0100 Modulates Cancer Cell Aggression Behavior of MDA-MB-231 through Microtubule and Heat Shock Proteins
Spetzler The KIAA0100 gene was identified in the human immature myeloid cell line cDNA library. Recent studies have shown that its expression is elevated in breast cancer and associated with more aggressive cancer types as well as poor outcomes. However, its cellular and molecular function is yet to be understood. Here we show that silencing KIAA0100 by siRNA in the breast cancer cell line MDA-MB-231 significantly reduced the cancer cells’ aggressive behavior, including cell aggregation, reattachment, cell metastasis and invasion. Most importantly, silencing the expression of KIAA0100 particularly sensit...
Source: Cancers - June 4, 2018 Category: Cancer & Oncology Authors: Zhenyu Zhong Vaishali Pannu Matthew Rosenow Adam Stark David Spetzler Tags: Article Source Type: research

Cancers, Vol. 10, Pages 80: Aptamer Therapeutics in Cancer: Current and Future
mi Tanaka Aptamer-related technologies represent a revolutionary advancement in the capacity to rapidly develop new classes of targeting ligands. Structurally distinct RNA and DNA oligonucleotides, aptamers mimic small, protein-binding molecules and exhibit high binding affinity and selectivity. Although their molecular weight is relatively small—approximately one-tenth that of monoclonal antibodies—their complex tertiary folded structures create sufficient recognition surface area for tight interaction with target molecules. Additionally, unlike antibodies, aptamers can be readily chemically synthesized and modifi...
Source: Cancers - March 19, 2018 Category: Cancer & Oncology Authors: Yoshihiro Morita Macall Leslie Hiroyasu Kameyama David Volk Takemi Tanaka Tags: Review Source Type: research

Cancers, Vol. 9, Pages 137: STAT3 but Not HIF-1 α Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line
This study has demonstrated that, in MDA-MB-231 cells, STAT3 rather than HIF-1α is important in mediating HICR to cisplatin.
Source: Cancers - October 14, 2017 Category: Cancer & Oncology Authors: Hoda Soleymani Abyaneh Nidhi Gupta Aneta Radziwon-Balicka Paul Jurasz John Seubert Raymond Lai Afsaneh Lavasanifar Tags: Article Source Type: research

Cancers, Vol. 8, Pages 111: The Enrichment of Survivin in Exosomes from Breast Cancer Cells Treated with Paclitaxel Promotes Cell Survival and Chemoresistance
The generation and release of membrane-enclosed packets from cancer cells, called extracellular vesicles (EVs), play important roles in propagating transformed phenotypes, including promoting cell survival. EVs mediate their effects by transferring their contents, which include specific proteins and nucleic acids, to target cells. However, how the cargo and function of EVs change in response to different stimuli remains unclear. Here, we discovered that treating highly aggressive MDAMB231 breast cancer cells with paclitaxel (PTX), a chemotherapy that stabilizes microtubules, causes them to generate a specific class of EV, ...
Source: Cancers - December 8, 2016 Category: Cancer & Oncology Authors: Bridget Kreger Eric Johansen Richard Cerione Marc Antonyak Tags: Article Source Type: research